KRAS mutations are one of the most frequent oncogenic mutations of all human cancers, being more prevalent in pancreatic, colorectal, and lung cancers. Intensive efforts have been encouraged in order to understand the effect of KRAS mutations, not only on tumor cells but also on the dynamic network composed by the tumor microenvironment (TME). The relevance of the TME in cancer biology has been increasing due to its impact on the modulation of cancer cell activities, which can dictate the success of tumor progression. Here, we aimed to clarify the pro- and anti-inflammatory role of KRAS mutations over the TME, detailing the context and the signaling pathways involved. In this review, we expect to open new avenues for investigating the poten...
For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to therapeutic strategies ...
KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refr...
Lung cancer is a highly mutated tumour type in which, if effective, cancer immunotherapies have prov...
KRAS mutations are one of the most frequent oncogenic mutations of all human cancers, being more pre...
Current evidence strongly suggests that cancer cells depend on the microenvironment in order to thri...
Current evidence strongly suggests that cancer cells depend on the microenvironment in order to thri...
Mutations in KRAS are among the most frequent aberrations in cancer, including colon cancer. KRAS di...
KRAS, one of the RAS protein family members, plays an important role in autophagy and apoptosis, thr...
KRAS is a driver mutation for malignant transformation. It is found in 30% of all cancers and in 90%...
がん進展制御研究所Mutations in Kirsten rat-sarcoma (KRAS) are well appreciated to be major drivers of human c...
AbstractMutations in the KRAS oncogene represent one of the most prevalent genetic alterations in co...
KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been approved t...
Rationale: KRAS is the most common and, simultaneously, the most ambiguous oncogene implicated in hu...
KRAS is mutated in about 20-25% of all human cancers and especially in pancreatic, lung and colorect...
: Non-small cell lung cancer (NSCLC) represents the perfect paradigm of 'precision medicine' due to ...
For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to therapeutic strategies ...
KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refr...
Lung cancer is a highly mutated tumour type in which, if effective, cancer immunotherapies have prov...
KRAS mutations are one of the most frequent oncogenic mutations of all human cancers, being more pre...
Current evidence strongly suggests that cancer cells depend on the microenvironment in order to thri...
Current evidence strongly suggests that cancer cells depend on the microenvironment in order to thri...
Mutations in KRAS are among the most frequent aberrations in cancer, including colon cancer. KRAS di...
KRAS, one of the RAS protein family members, plays an important role in autophagy and apoptosis, thr...
KRAS is a driver mutation for malignant transformation. It is found in 30% of all cancers and in 90%...
がん進展制御研究所Mutations in Kirsten rat-sarcoma (KRAS) are well appreciated to be major drivers of human c...
AbstractMutations in the KRAS oncogene represent one of the most prevalent genetic alterations in co...
KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been approved t...
Rationale: KRAS is the most common and, simultaneously, the most ambiguous oncogene implicated in hu...
KRAS is mutated in about 20-25% of all human cancers and especially in pancreatic, lung and colorect...
: Non-small cell lung cancer (NSCLC) represents the perfect paradigm of 'precision medicine' due to ...
For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to therapeutic strategies ...
KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refr...
Lung cancer is a highly mutated tumour type in which, if effective, cancer immunotherapies have prov...